Navigation Links
Gardasil, Other New Products Spur Strong Vaccine Sales in 2007
Date:4/7/2008

NEW YORK, April 7, 2008 /PRNewswire/ -- Stronger than anticipated revenues for flu vaccines, and the surprising commercial success of Merck's Gardasil for HPV, which causes most cervical cancers, has led to a healthy $16.3 billion in vaccine sales in 2007. This represents an increase of 38% over 2006 sales of $11.7 billion, according to Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry, a new market research study and reforecast of the vaccine market from Kalorama Information.

According to the report, new products approved in recent years, in particular Gardasil, but also RotaTeq, Pentacel, Zostavax and FluMist, are now having an impact on the market. These new products, combined with a continued emphasis on flu vaccines in the U.S. healthcare system, have created a healthy environment for vaccine products.

Five major players -- Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Wyeth and Novartis -- dominate vaccine sales. At these companies, as well as smaller producers, Kalorama Information has found increased interest in vaccines, and a willingness to look at products for conditions not historically addressed with vaccines, including diabetes, cancer and smoking cessation. Given this trend and strong sales, Kalorama Information expects vaccine sales to more than double in five years.

"You might call it a 'Gardasil Effect'," says Bruce Carlson, publisher of Kalorama Information. "R&D departments are more confident about investing in a vaccine product now than in the past because a strong marketing precedent has been established. Expect to see new vaccine products, and perhaps new companies in the market."

Kalorama Information's new report Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry reforecasts the market for this highly profitable drug segment and addresses the dramatic changes taking place. The report covers current world revenues
'/>"/>

SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Identification of dopamine mother cells could lead to future Parkinsons treatments
2. Mother-Child Bond Affects Quality of Conflict Resolution
3. Snack Brothers Distributors to Sell New HEALTHYCAL+ Bottled Water
4. Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Competes in Ironman Arizona in Tempe
5. Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand
6. Fetal Cells Detected in Mothers Blood Years After Donor Egg Pregnancies
7. Wounded Warriors Rig for Skiing, Rock Climbing, Other Winter Sports
8. Mother-child attachment, childrens temperament play a role in terrible 2 conflicts
9. YogaPro Celebrates Mothers Day with a Photo Contest to Win YogaToes(R) Foot Care Exercisers to Soothe and Beautify Moms Feet
10. Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions
11. RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for More than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Though the number of jobs created i... companies reported a different kind of slowdown: ...s months. , Seattle, WA (...created in the medical field slowed in June overal...ind of slowdown that will be music to the ears of ...
(Date:7/25/2008)... supporting the US Department of Defense and Feder... Phoenix. Operation Golden Phoenix is a, four-da...ned to assist, federal, state and local agencies w...os. Dataline is providing a vital, ad-hoc, secure ... use during the exercise., NORFOLK, Va., July 25 ...
(Date:7/25/2008)...elationship Based on Significant Improvements in M...MDdatacor, Inc., a leader in health,care quality m..., today,announced it has entered into a long-term ...rt Wellmark,s Collaboration on Quality(SM) Incent ...ion between Wellmark and,primary care clinicians t...
(Date:7/25/2008)...URG, Ill., July 25 /PRNewswire/ -- Sagent Pharmace...utical company, today announced that it,has launch...arrhythmic,indicated for the treatment and prophyl...ion and hemodynamically unstable ventricular,tachy... heart beat.,Sagent,s amiodarone HCl injection wil...
Breaking Medicine News(10 mins):Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...s of energy loss during aerobic exercises and this...w our bodies react to exercise programs is genetic...cising like the level of blood glucose in the body...publishing the works of scientists from Washington...
...dies, a part of the Zydus group, has launched Flud...onic lymphocytic leukemia. Chronic Lymphocytic Leu...a serious, progressive disease, which at present h...very uncommon in young people and becomes progress...
...s that the smokers may differ in their cravings// ... to smoking. Researchers have found that the urge ... smokers according to the brain responses to the s...e University Medical Center had looked into the br...
...nts to produce vaccines and other treatments for m...nd they hope to start clinical trials by the year ...will be of greatest benefit to developing nations ...very poor at the same time keeping in mind that hu...
Other Medicine News:Health News:Producing Vaccines from genetically modified crops 2
(Date:7/22/2008)...pment Initiative bring MJFF,s,current active indus...,2009, NEW YORK, July 22 /PRNewswire-USNewswire/...ansformative treatments and a cure for Parkinson,s...son,s Research has awarded,$2.7 million in total f...were granted under MJFF,s Therapeutics Development...
(Date:7/22/2008)...acy of Treating Patients with ...GIN-SI, South Korea, July 22 /-,Jenne... and its South,Korean partner Green Cross Corp., a...clinical trial of its first-in-class lead product ...rated and resulted in clear,anti-cancer efficacy i...
(Date:7/22/2008)...dra(R) Resulted in Significant, Reductions in A1C ...orithm Used, BRI...om the "Adjust to,Target in Type 2 Diabetes: Compa...ng for Adjustment of Mealtime Insulin Glulisine" s...ciation,s (ADA) medical journal,Diabetes Care. Th...
(Date:7/22/2008)...RNewswire/ -- Hyperion,Therapeutics, Inc. today an...n its Phase 1/2 clinical trial to evaluate the saf...f HPN-100 (formally called GT4P) versus,BUPHENYL(R...cle disorders,(UCD). The company plans to announce...ar., (Logo: http://www.newscom.com/cgi-bin/prnh/...
Breaking Medicine Technology:Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 1GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 2GenOdyssee Receives Notice of Allowance from U S Patent Office for Improved Interferon Alpha Aimed at Hepatitis C 11888 3St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 1St Valentines Day Wishes 3A Perfume 3F Jewelry 3F Labiaplasty 3F 11886 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 1Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 2Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 3Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis 3284 4Pharmaxis to Apply to Market Bronchitol in Australia 3283 1Pharmaxis to Apply to Market Bronchitol in Australia 3283 2Pharmaxis to Apply to Market Bronchitol in Australia 3283 3
...n three investigational,agents (VEGF Trap, S-1 and...SCO meeting, BRIDGEWATER, N.J., May 29, 2007 /PRNe...y that a total of 375 abstracts,indicative of its ...d Annual Meeting of the American Society of Clinic... 2007). The results from key,studies involving the...
...INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today...of INNO-406, an orally bioavailable dual Bcr-Abl a...r,treatment-intolerant chronic myelogenous leukemi...of Clinical Oncology Annual,Meeting. The meeting t...hicago, Illinois., Information related to the pres...
Other Medicine Technology:Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 2Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 3Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 4Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 5Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 6Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 7Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 8Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 9Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 10Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 11Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research 12Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
FM Series Oxygen Flowmeters with Power Take Off, ,Options: , For security chain, add suffix S to model number. Example: FM107S. , For Canadian Color-Code, add suffix C to model number. Example: FM10
FM Style Neonatal Flowmeters (Brass Body)
...te offers innovative proficiency testing solutions...upport. As a result, API is one of the largest pro...12,000 laboratories enrolled. Here are just some o...roficiency Testing, Free CME/CMLE Credits Spons...
... for the professional ophthalmic photographer. Int... slit and background illumination, all controlled ... slit lamp joystick, as well as adaptors allowing ...nal level digital and 35 mm cameras, ensure ophtha...
Medicine Products: